Recent Updates
Recently added Catalysts
BIIB Positive Sentiment

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Eisai Co., Ltd. and Biogen Inc. announced that Canada's Drug Agency has issued a final positive recommendation for public reimbursement of LEQEMBI (lecanemab) for early Alzheimer's disease. This decision is expected to improve access to the treatment for eligible patients in Canada, marking a significant advancement in Alzheimer's care.

Market Sentiment Analysis

POSITIVE FACTORS

  • CDA-AMC supports public reimbursement for LEQEMBI.
  • This recommendation enhances access for eligible patients.
  • It marks a significant step in Alzheimer's treatment in Canada.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis

Full Press Release Details

An Important Step Forward for Access to LEQEMBI® for Eligible Patients in Canada TOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public

Frequently Asked Questions

What is LEQEMBI?

LEQEMBI (lecanemab) is a treatment for early Alzheimer's disease.

Who issued the recommendation for LEQEMBI?

Canada's Drug Agency (CDA-AMC) issued the recommendation.

What does the recommendation support?

It supports public reimbursement of LEQEMBI for eligible patients.

Why is this recommendation significant?

It enhances access to Alzheimer's treatment for patients in Canada.

ShareAdd on Google
Tags: BIIB Viatris Investor Conferences Healthcare LEQEMBI lecanemab Alzheimer's disease Canada CDA-AMC
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$3878M liquidity · $0M/mo burn
Low dilution risk
Lead asset
AlefaceptPhase 3
Chronic Plaque Psoriasis →

Catalyst track record

+34%
best trade around BIIB's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for BIIB.

See every catalyst's timing & PoA →